

Company registration number: 11119884

Medics 4 Rare Diseases Ltd

Company limited by guarantee

Unaudited filleted financial statements

31 December 2018

Medics 4 Rare Diseases Ltd

Company limited by guarantee

Contents

Directors and other information

Statement of financial position

Notes to the financial statements

Medics 4 Rare Diseases Ltd

Company limited by guarantee

Directors and other information

Directors

Mrs T Collin-Histed

Dr D R Fine

(Appointed 25 July 2018)

Mr C J France

(Appointed 25 July 2018)

Dr O H Grant

(Appointed 25 July 2018)

Mr D C Jeffries

(Appointed 25 July 2018)

Miss S K Bhachu

(Resigned 3 September 2018)

Dr L M R McKay

(Resigned 31 August 2018)

Secretary

Dr L M R McKay

Company number

11119884

Registered office

8 Silver Street

Dursley

Gloucestershire

GL11 4ND

Medics 4 Rare Diseases Ltd

Company limited by guarantee

Statement of financial position

31 December 2018

	Note	2018	£
Current assets			
Cash at bank and in hand		30,971	
		<u>30,971</u>	
Creditors: amounts falling due within one year	6	(4,187)	
		<u>26,784</u>	26,784
Net current assets			<u>26,784</u>
Total assets less current liabilities			<u>26,784</u>
Net assets			<u>26,784</u>
Capital and reserves			
Profit and loss account			26,784
Members funds			<u>26,784</u>

For the year ending 31 December 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

These financial statements were approved by the board of directors and authorised for issue on 04 September 2019 , and are signed on behalf of the board by:

Mr C J France

Director

Company registration number: 11119884

Medics 4 Rare Diseases Ltd

Company limited by guarantee

Notes to the financial statements

Year ended 31 December 2018

1. General information

The company is a private company limited by guarantee, registered in England and Wales. The address of the registered office is 8 Silver Street, Dursley, Gloucestershire, GL11 4ND.

2. Statement of compliance

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Income

Income represents donations and sponsorships which are recognised when receivable.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

4. Limited by guarantee

Medics 4 Rare Diseases Ltd is a company limited by guarantee and accordingly does not have a share capital. Every member of the company undertakes to contribute such amount as may be required not exceeding £1 to the assets of the company in the event of its being wound up while he or she is a member, or within one year after he or she ceases to be a member.

5. Staff costs

The average number of persons employed by the company during the year amounted to 1

The aggregate payroll costs incurred during the year were:

	2018
	£
Wages and salaries	3,950
	<hr/>

6. Creditors: amounts falling due within one year

	2018
	£
Other creditors	4,187
	<hr/>

7. Events after the end of the reporting period

The company received charitable status on 20 June 2019.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.